Summary:
- MACD is crossing MACD signal line at 0.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today the public...
—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims to expand Capricor’s manufacturing capacity for potential late-stage clinical trials and commercialization——Process development to take place in Lonza’s Houston (TX) center of excellence—LOS ANGELES and BASEL, Switzerland, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, (NASDAQ: CAPR), a cli...
Trial Assessing Ability of Capricor’s Cardiac Cell Therapy, CAP-1002, to Reduce the Cytokine Storm Associated with Severe COVID-19LOS ANGELES, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell- and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that the independent Data and Safety...
\- Data Expected Second Quarter 2021 - - The INSPIRE Trial Is Designed to Assess the Ability of CAP-1002 to Modulate the Cytokine Storm Associated With Severe COVID-19 -LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced tod...
Exosome Platform Technology -Announced Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19- -Novel Vaccine Induced Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- -Development of Safe, Non-toxic Exosome Formulation Capable of Delivering Functional mRNA in vitro and in vivo- -Platform Expansion Underway Using Engineered Exosomes-Duchenne Muscular Dystrophy Program -In Discussions with FDA on Next Steps in Pathway Forward-CAP-1002 for COVID-19 -Patient Screenin...
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Capricor Therapeutics, Inc.